Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort.
DXA scan
HIV infection
adverse events
bone mineral density
dolutegravir
real-life setting
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
04
2020
accepted:
27
06
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Few data exist about the effect of dolutegravir (DTG) on bone mineral density (BMD) in real life. The aim of this study was to determine rates of change in BMD over time in people living with HIV (PLWH) treated with DTG. The SCOLTA project is a multicenter observational study enrolling HIV-infected people who start newly commercialized drugs prospectively, with the aim of identifying toxicities and adverse events (AE) in a real-life setting. Dual-energy X-ray absorptiometry at the femoral neck (FN) and lumbar spine (LS) was performed at study entry (baseline, BL) and after 96 weeks. Percentage BMD change from BL was evaluated using a general linear model, including factors potentially associated with bone loss. One hundred and sixty PLWH were enrolled (26.3% female, mean age 49.9 ± 11.2 years) from April 2015 to April 2017. Overall, we could calculate BMD change from baseline, for at least one site, in 133 subjects (83.1%). After a median of 102 weeks (IQR: 90-110), mean FN BMD increased, but not significantly, whereas LS BMD showed a significant mean increase of 13.1 (95% confidence interval, CI: 1.7-24.6) mg/cm Dolutegravir-containing regimens could reduce the negative impact of antiretroviral therapy on bone, especially in patients with low BMD.
Identifiants
pubmed: 32765005
doi: 10.2147/IDR.S260449
pii: 260449
pmc: PMC7368553
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2291-2300Informations de copyright
© 2020 Bonfanti et al.
Déclaration de conflit d'intérêts
PB has received consultancy and/or speakers’ fees from Gilead Sciences, Janssen, Merck Sharp & Dohme and ViiV. GVDS has received travel grants, and speaker’s honoraria from Gilead, ViiV Healthcare, Janssen-Cilag and MSD. ER has acted as statistician consultation for ViiV. BMC received grants, travel grants and speaker’s honoraria from Abbvie, Bristol‐Myers Squibb, Gilead, ViiV, Janssen‐Cilag and Merck Sharp & Dohme, was advisor for Bristol‐Myers Squibb, Gilead, ViiV, Janssen‐Cilag and Merck Sharp & Dohme and received fellowship from ViiV and Gilead. GM has acted as advisor for Gilead Sciences, Janssen and Merck Sharp and Dohme and ViiV Healthcare and has received speakers’ honoraria from Gilead Sciences, Merck Sharp and Dohme, Janssen and ViiV Healthcare. NS received grants for consultancy from ViiV Healthcare, and grants for participations at meetings from Gilead and Janssen. ADV, BM, ES, GO, VC and CD report no conflicts of interest in this work.
Références
Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4576-89
pubmed: 26698255
HIV Med. 2014 Jul;15(6):373-80
pubmed: 24460797
Int J STD AIDS. 2019 Oct;30(11):1042-1048
pubmed: 31431155
Eur Rev Med Pharmacol Sci. 2013 Jul;17(14):1938-50
pubmed: 23877860
AIDS. 2006 Nov 14;20(17):2165-74
pubmed: 17086056
J Infect Dis. 2015 Oct 15;212(8):1241-9
pubmed: 25948863
AIDS. 2017 Jan 28;31(3):457-459
pubmed: 28079545
J Intern Med. 2016 Oct;280(4):350-8
pubmed: 27272530
Clin Infect Dis. 2011 Feb 1;52(3):396-405
pubmed: 21217186
AIDS. 2013 Jul 31;27(12):1949-57
pubmed: 24126140
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):317-20
pubmed: 15980692
Lancet HIV. 2018 Jul;5(7):e357-e365
pubmed: 29925489
Lancet. 2015 Jun 27;385(9987):2606-15
pubmed: 25890673
AIDS. 2015 Nov 28;29(18):2459-64
pubmed: 26355674
Antiviral Res. 2019 Sep;169:104552
pubmed: 31283942
Infect Drug Resist. 2019 May 23;12:1385-1391
pubmed: 31213857
Infez Med. 2018 Dec 1;26(4):336-340
pubmed: 30555137
AIDS. 2017 Nov 28;31(18):2503-2514
pubmed: 29112070
Lancet Infect Dis. 2016 Jan;16(1):43-52
pubmed: 26538525
Int J Antimicrob Agents. 2015 Mar;45(3):289-94
pubmed: 25476452
Osteoporos Int. 1994 Nov;4(6):368-81
pubmed: 7696835
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218
pubmed: 28282300
Antivir Ther. 2017;22(4):295-305
pubmed: 28401876
AIDS Res Hum Retroviruses. 2018 Apr;34(4):337-342
pubmed: 29368537
PLoS One. 2014 Aug 29;9(8):e106221
pubmed: 25170938
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):163-72
pubmed: 21826011
Nature. 1999 Nov 18;402(6759):304-9
pubmed: 10580503
Clin Infect Dis. 2015 Apr 15;60(8):1242-51
pubmed: 25609682
Lancet. 2017 Nov 4;390(10107):2063-2072
pubmed: 28867497
AIDS. 2018 Feb 20;32(4):477-485
pubmed: 29239893
Bonekey Rep. 2015 Feb 11;4:636
pubmed: 25709813
J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184
pubmed: 27673443
Osteoporos Int. 2003 Dec;14(12):978-82
pubmed: 14530829
AIDS Res Hum Retroviruses. 2020 Jan;36(1):19-26
pubmed: 31502468
Clin Infect Dis. 2011 Feb 1;52(3):406-8
pubmed: 21217187
JBMR Plus. 2018 Jun 20;2(5):247-256
pubmed: 30283906
Lancet HIV. 2015 Nov;2(11):e464-73
pubmed: 26520926
PLoS One. 2015 Apr 21;10(4):e0124168
pubmed: 25898185
Curr Opin HIV AIDS. 2016 May;11(3):277-84
pubmed: 26890209
AIDS. 2016 Jan 28;30(3):405-14
pubmed: 26760232
J Antimicrob Chemother. 2014 Dec;69(12):3368-71
pubmed: 25125679
Q J Nucl Med Mol Imaging. 2004 Mar;48(1):39-48
pubmed: 15195003
Clin Infect Dis. 2010 Oct 15;51(8):963-72
pubmed: 20828304